- Home
- BFRI vs INAB Comparison
BFRI vs INAB Comparison
Compare BFRI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- INAB
- Stock Information
- Founded
- BFRI 1997
- INAB 2016
- Country
- BFRI United States
- INAB United States
- Employees
- BFRI N/A
- INAB N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- INAB Health Care
- Exchange
- BFRI Nasdaq
- INAB Nasdaq
- Market Cap
- BFRI 7.9M
- INAB 7.5M
- IPO Year
- BFRI 2021
- INAB 2021
- Fundamental
- Price
- BFRI $0.93
- INAB $2.25
- Analyst Decision
- BFRI Strong Buy
- INAB Strong Buy
- Analyst Count
- BFRI 1
- INAB 2
- Target Price
- BFRI $2.75
- INAB $108.00
- AVG Volume (30 Days)
- BFRI 82.9K
- INAB 119.6K
- Earning Date
- BFRI 08-13-2025
- INAB 08-07-2025
- Dividend Yield
- BFRI N/A
- INAB N/A
- EPS Growth
- BFRI N/A
- INAB N/A
- EPS
- BFRI N/A
- INAB N/A
- Revenue
- BFRI $37,997,000.00
- INAB N/A
- Revenue This Year
- BFRI $11.75
- INAB N/A
- Revenue Next Year
- BFRI $17.09
- INAB N/A
- P/E Ratio
- BFRI N/A
- INAB N/A
- Revenue Growth
- BFRI 14.28
- INAB N/A
- 52 Week Low
- BFRI $0.54
- INAB $1.98
- 52 Week High
- BFRI $2.22
- INAB $21.21
- Technical
- Relative Strength Index (RSI)
- BFRI 50.53
- INAB 47.06
- Support Level
- BFRI $0.88
- INAB $2.01
- Resistance Level
- BFRI $0.96
- INAB $2.38
- Average True Range (ATR)
- BFRI 0.09
- INAB 0.14
- MACD
- BFRI -0.02
- INAB 0.03
- Stochastic Oscillator
- BFRI 16.67
- INAB 45.76
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.